Canterbury Health Laboratories, Canterbury District Health Board, Christchurch, New Zealand
Christchurch Sexual Health Services, Canterbury District Health Board, Christchurch, New Zealand.
J Clin Microbiol. 2017 Nov;55(11):3242-3248. doi: 10.1128/JCM.01087-17. Epub 2017 Sep 6.
has been associated with infections of the genitourinary tract, and prevalence is secondary to The clinical observation of increasing treatment failure indicating antibiotic resistance, especially in cases of recurrent urethritis, has been confirmed by molecular testing. Mutations in the 23S rRNA gene can cause macrolide resistance, and topoisomerase/gyrase mutations can cause fluoroquinolone resistance. In this study, 115 DNA-positive samples were analyzed. Eighty-nine (77.4%) samples had a 23S rRNA mutation present, and 26 (22.6%) were wild type (no resistance mutation). Fluoroquinolone mutation screening was performed on 86 (74.8%) of the 115 samples, of which 20 (23.3%) samples had a mutation or mutations associated with increased resistance. This study shows the increasing antibiotic resistance in New Zealand and the need for appropriate guidelines to treat at-risk patients.
已与泌尿生殖道感染相关,其流行率继发于 分子检测证实了临床观察到的治疗失败率增加表明抗生素耐药性,尤其是在复发性尿道炎病例中。23S rRNA 基因突变可导致大环内酯类耐药,拓扑异构酶/回旋酶基因突变可导致氟喹诺酮类耐药。在这项研究中,分析了 115 份 DNA 阳性样本。89 份(77.4%)样本存在 23S rRNA 突变,26 份(22.6%)为野生型(无耐药突变)。对 115 份样本中的 86 份(74.8%)进行了氟喹诺酮类药物突变筛查,其中 20 份(23.3%)样本存在与耐药性增加相关的突变或突变。本研究表明新西兰的抗生素耐药性不断增加,需要制定适当的指南来治疗高危患者。